There are currently 81 active clinical trials seeking participants for Atrial Fibrillation research studies. The states with the highest number of trials for Atrial Fibrillation participants are Florida, California, Ontario and Texas.
High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation
NCT03444337
Recruiting
Patients undergoing FIRM guided ablation of atrial fibrillation will undergo high resolution MRI imaging to determine correlation of underlying anatomic fibrotic regions with FIRM targeted sites for ablation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/05/2024
Locations: Ohio State University, Columbus, Ohio
Conditions: Atrial Fibrillation
Register for Updates
Biomarkers of Acute Stroke in Clinic
NCT03897478
Recruiting
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out, as defined by TOAST classification of subtypes of acute ischemic stroke. Aim 2: In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
09/26/2023
Locations: Ohio Health Riveside Methodist Hospital, Columbus, Ohio
Conditions: Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Register for Updates
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
NCT06802081
Recruiting
This is a single center randomized double blind controlled study of patients (BMI\> 30 kg/m2) with obesity and Atrial Fibrillation (AFIB) randomized to Tirzepatide vs. placebo. It is expected that the significant weight loss with Tirzepatide will result in improved control, management, symptom severity, and burden of AFIB at 12 months.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/10/2025
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Atrial Fibrillation, Obesity
Register for Updates
Intracardiac Echocardiography Guided Watchman Device Implant
NCT06007872
Recruiting
This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Atrial Fibrillation, Left Atrial Appendage Thrombosis
Register for Updates
Development of CIRC Technologies
NCT05654272
Recruiting
Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which mark... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cardiovascular Innovation Research Center, Cleveland, Ohio
Conditions: Cardiovascular Diseases, Heart Failure, Ischemic Heart Disease, Non-ischemic Cardiomyopathy, Valvular Heart Disease, Metabolic Cardiomyopathy, Congenital Heart Disease, Aortic Diseases, Atrial Fibrillation, Ventricular Fibrillation
Register for Updates
The CONFORM Pivotal Trial
NCT05147792
Recruiting
The CLAAS® device will be evaluated for safety and efficacy by establishing its performance is non-inferior to the commercially available WATCHMAN® and Amulet™ left atrial appendage closure devices in patients with non-valvular atrial fibrillation. Patients who are eligible for the trial will be randomized to receive either the CLAAS device or the WATCHMAN or Amulet™ devices and will be followed for 5 years after device implant.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Grandview Medical Center, Birmingham, Alabama +52 locations
Conditions: Atrial Fibrillation, Stroke
Register for Updates
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients with Esophageal Cancer
NCT06067438
Recruiting
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer. Atrial fibrillation (AF) is an irregular heart rhythm, usually associated with a rapid rate, that is caused by abnormal electrical activity within the atria. AF is the most common complication after MIE for esophageal cancer. There has never been a study of AF after MIE that has used unbiased assignment of patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Atrial Fibrillation, Esophageal Carcinoma
Register for Updates
Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High-Risk Heart Failure Patients
NCT04818645
Recruiting
Patients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities for early AF detection and subsequent stroke prevention in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long term arrhythmia information via remote monitoring. The ASSERT-AF study seeks to accurately define the burden of AF and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Atrial Fibrillation, Heart Failure
Register for Updates
320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.
NCT06308094
Recruiting
This study explores the relationship between myocardial fibrosis and patient outcomes in Atrial Fibrillation (AF), specifically after catheter ablation. It aims to use Cardiac CT, an accessible tool, to measure left ventricular extracellular volume (ECV) as an indicator of fibrosis. The study will assess if higher ECV levels correlate with increased risks of AF recurrence, hospitalization, and poor cardiac function recovery. Positive findings could make ECV a key factor in deciding AF treatment... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/04/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Atrial Fibrillation
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +1040 locations
Conditions: Atrial Fibrillation
Register for Updates
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
NCT05836987
Recruiting
REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
03/01/2025
Locations: Banner University, Phoenix, Arizona +83 locations
Conditions: Atrial Fibrillation
Register for Updates
WIBOFA - Validation of SCT02 With ECG-App for Detection of AF
NCT06351761
Recruiting
The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings ECG-app in the automatic detection of atrial fibrillation
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/27/2025
Locations: FWD Clinical Research, Boca Raton, Florida +3 locations
Conditions: Atrial Fibrillation
Register for Updates